Observational studyUnited European gastroenterology journal2026
EUROHELICAN-The First Helicobacter Pylori Screen-and-Treat Population-Based Study in Young Adults in Europe.
Observational study in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06216639 (EU4Health Project Eurohelican), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EU4Health Project Eurohelican: A Single-center Prospective Feasibility Study of the Proposed Test-and-treat Preventive Screening Program in Younger Slovenian Participants Aged 30-34 Years With or Without Helicobacter Pylori Infection
Who cites it
2 citing papers in PubMed.
- A real-world workplace-based screening for Helicobacter pylori infection: the HPOS study.Cancer causes & control : CCC · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMost gastric cancer cases are attributable to chronic Helicobacter pylori (H. pylori) infection and can theoretically be prevented.
objectiveIn the EUROHELICAN project, we aimed to assess the feasibility, acceptability, effectiveness, and adverse events of a Helicobacter pylori screen-and-treat program in the 30-34-year age group for the first time in Europe.
designThe study was conducted in the Community Healthcare Center dr. Adolf Drolc Maribor, following the methodology prepared by the National Institute of Public Health. We invited asymptomatic individuals aged 30-34 to be tested for H. pylori IgG antibodies; positive results were confirmed by urea breath test (UBT).
results2102 participants accepted the invitation. The response rate was 24.4% (95% CI: 23.2-25.5), which was higher in women-28.1% (95% CI: 26.4-29.8) than in men-20.5% (95% CI: 0.19.0-22.1, p < 0.001). The serological prevalence of H. pylori infection was 14.2% (95% CI: 12.7-15.9). A confirmatory urea breath test (UBT) was positive in 83.7% of serology-positive patients. The eradication rate of 14-day bismuth-based quadruple therapy (esomeprazole 40 mg BID, amoxicillin 500 mg, metronidazole 400 mg and bismuth oxide 120 mg, all QID) was 94.7% (95% CI: 89.5-97.9). Adverse events (AEs) during treatment were reported more frequently in women (38.8%, 95% CI: 28.1-50.3) than in men (21.5%, 95% CI: 12.3-33.5; p < 0.05).
conclusionH. pylori screening and-treat program in 30-34 age group in Slovenia is feasible; H. pylori treatment is very effective with acceptable rate of AEs. Different approaches to raising public awareness are needed to increase participation rates.
trial registrationEU PAS number of HMA-EMA RWD Catalog: EUPAS107327, Study ID: 108428; ClinicalTrials.gov ID: NCT06216639, Protocol ID: EUROHELICAN01.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.